10.1111/dom.12802 Summary Keywords type 2 diabetes, DPP-4 inhibitors, oral antidiabetic, incretin-based therapy, gliptin, combination therapy Citation Gallwitz B (2019) Clinical Use of DPP-4 Inhibitors
Ozempic and other GLP-1 receptor agonist medications have changed how we treat type 2 diabetes and weight loss
We surface safe, lower-cost therapeutic alternatives, including for GLP-1s, so physicians can make informed choices and reduce unnecessary spend
The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
and the content it produces is for informational purposes only
When used as a medication, GLP-1 receptor agonists do more than just control hungerthey also influence fat storage and metabolism at a cellular level